Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOFACITINIB Cause Maternal exposure during pregnancy? 3,981 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 3,981 reports of Maternal exposure during pregnancy have been filed in association with TOFACITINIB (XELJANZ XR). This represents 2.6% of all adverse event reports for TOFACITINIB.

3,981
Reports of Maternal exposure during pregnancy with TOFACITINIB
2.6%
of all TOFACITINIB reports
1,185
Deaths
1,495
Hospitalizations

How Dangerous Is Maternal exposure during pregnancy From TOFACITINIB?

Of the 3,981 reports, 1,185 (29.8%) resulted in death, 1,495 (37.6%) required hospitalization, and 1,428 (35.9%) were considered life-threatening.

Is Maternal exposure during pregnancy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 3,981 reports have been filed with the FAERS database.

What Other Side Effects Does TOFACITINIB Cause?

Drug ineffective (30,382) Pain (21,659) Condition aggravated (16,925) Arthralgia (15,640) Fatigue (13,551) Rheumatoid arthritis (12,277) Off label use (11,736) Headache (11,061) Joint swelling (10,686) Malaise (9,040)

What Other Drugs Cause Maternal exposure during pregnancy?

CERTOLIZUMAB PEGOL (9,013) ADALIMUMAB (7,518) PREDNISONE (6,587) METHOTREXATE (6,223) RITUXIMAB (6,093) INFLIXIMAB (6,061) HYDROXYCHLOROQUINE (5,809) FOLIC ACID (5,768) TOCILIZUMAB (5,737) LEFLUNOMIDE (5,643)

Which TOFACITINIB Alternatives Have Lower Maternal exposure during pregnancy Risk?

TOFACITINIB vs TOFERSEN TOFACITINIB vs TOLNAFTATE TOFACITINIB vs TOLODODEKIN ALFA TOFACITINIB vs TOLTERODINE TOFACITINIB vs TOLVAPTAN

Related Pages

TOFACITINIB Full Profile All Maternal exposure during pregnancy Reports All Drugs Causing Maternal exposure during pregnancy TOFACITINIB Demographics